LEMAITRE VASCULAR INC (LMAT) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001158895 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | $70.4M | $17.1M | $0.74 | Filing |
| Mar 31, 2026 | May 5, 2026 | $66.6M | $15.7M | $0.68 | Filing |
| Dec 31, 2025 | Feb 25, 2026 | $64.5M | $15.5M | $0.69 | Filing |
| Sep 30, 2025 | Nov 6, 2025 | $61.0M | $17.4M | $0.75 | Filing |
| Jun 30, 2025 | Aug 5, 2025 | $64.2M | $13.8M | $0.60 | Filing |
| Mar 31, 2025 | May 1, 2025 | $59.9M | $11.0M | $0.48 | Filing |
| Dec 31, 2024 | Feb 27, 2025 | $55.7M | $11.1M | $0.48 | Filing |
| Sep 30, 2024 | Oct 31, 2024 | $54.8M | $11.1M | $0.49 | Filing |
What would LEMAITRE VASCULAR INC have to report for its valuation to change?
At $80.82, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 19.3% a year, to $6.91. On that path the next quarter needs diluted EPS near $0.89, against $0.75 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 19.3% | 19.3% |
| EPS needed in final year | $6.91 | $6.91 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. LMAT goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.